Literature DB >> 1382767

Cytokines and cancer.

S Malik, J Waxman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1382767      PMCID： PMC1882756          DOI： 10.1136/bmj.305.6848.265

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  22 in total

1.  Is there a common pathway mediating growth inhibition by TGF-beta and the retinoblastoma gene product?

Authors:  A B Roberts; S J Kim; M B Sporn
Journal:  Cancer Cells       Date:  1991-01

2.  Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

Authors:  C I Falkson; G Falkson; H C Falkson
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

Review 3.  Tumour necrosis factor: roles in cancer pathophysiology.

Authors:  S T Malik
Journal:  Semin Cancer Biol       Date:  1992-02       Impact factor: 15.707

4.  Cancer cachexia revisited: old problems and new perspectives.

Authors:  S F Lowry
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

5.  Cells secreting tumour necrosis factor show enhanced metastasis in nude mice.

Authors:  S T Malik; M S Naylor; N East; A Oliff; F R Balkwill
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.

Authors:  C Boutin; J R Viallat; N Van Zandwijk; J T Douillard; J C Paillard; J C Guerin; P Mignot; J Migueres; F Varlet; A Jehan
Journal:  Cancer       Date:  1991-04-15       Impact factor: 6.860

7.  In situ detection of tumour necrosis factor in human ovarian cancer specimens.

Authors:  M S Naylor; S T Malik; G W Stamp; T Jobling; F R Balkwill
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

8.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

9.  Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.

Authors:  S Wadler; B Lembersky; M Atkins; J Kirkwood; N Petrelli
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

10.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites.

Authors:  U Räth; M Kaufmann; H Schmid; J Hofmann; B Wiedenmann; A Kist; J Kempeni; E Schlick; G Bastert; B Kommerell
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162
View more
  5 in total

1.  Using cytokines.

Authors:  R Grimble
Journal:  BMJ       Date:  1992-09-12

Review 2.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

3.  Expression of selectin ligands by cutaneous squamous cell carcinoma.

Authors:  R W Groves; M H Allen; E L Ross; G Ahsan; J N Barker; D M MacDonald
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

Review 4.  Associations between physical activity and susceptibility to cancer: possible mechanisms.

Authors:  R J Shephard; P N Shek
Journal:  Sports Med       Date:  1998-11       Impact factor: 11.136

5.  The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

Authors:  T Palomares; P Bilbao; A Alonso-Varona; E Barberá-Guillem
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.